Atypical teratoid/rhabdoid tumors (AT/RTs) are aggressive pediatric brain tumors with a dismal prognosis. Median survival remains between 6 and 11 months despite intensive multimodality therapy. 1 This aggressive phenotype arises from a single genetic mutation in the SMARCB1 chromatin remodeling gene. 2 This mutation leads to aberrant regulation of thousands of genes likely leading to the overexpression of oncogenic drivers. 3 Identifying these oncogenic drivers can lead to new targeted therapies that may improve survival in AT/RT. We previously identified high-level activation of LIN28 and the RAS pathway in AT/RT. 4 LIN28 is a somatic cell reprogramming and stem cell factor that contributes to the aggressive nature of many tumors. 5 
mammalian target of rapamycin (mTOR) by suppressing the let-7 family of miRNAs. These let-7 miRNAs bind to and inhibit mRNAs that regulate key components of the mTOR pathway, including AKT and phosphatidylinositol-3 kinase (PI3K). [6] [7] [8] Kirsten rat sarcoma viral oncogene homolog (KRAS) itself can activate mTOR as well as mitogen-activated protein kinase (MAPK). 9 Mammalian TOR is a serine/threonine protein kinase that is a component of the PI3K cell survival pathway that regulates important cell functions such as metabolism, survival, and proliferation. 10, 11 It is overexpressed in many aggressive tumors, and elevated expression has been correlated with drug resistance and poor survival. [12] [13] [14] [15] [16] Mammalian TOR functions through 2 distinct complexes: mTORC1 and mTORC2-mTORC1 activation is canonically measured by detecting the phosphorylation of the 40S ribosomal protein subunit S6 kinase (S6K); mTORC2 phosphorylates and activates AKT at Ser473, as well as other targets. 17 The roles of mTORC1 and mTORC2 in tumorigenesis make these complexes attractive targets for pharmacologic inhibition.
TAK228 (formerly INK128, MLN0128, also known as sapanisertib) is a selective, highly potent, and orally bioavailable adenosine triphosphate (ATP) competitor of mTORC1 and mTORC2 which is in phase I and II clinical trials as a single agent and in combination therapy for patients with advanced solid tumors (NCT01899053, NCT01058707, NCT0133183, NCT02091531). Preclinical studies have shown that TAK228 has antitumor activity in a range of tumor types, including prostate cancer, B-cell leukemia, breast cancer, renal cell carcinoma, and bone and soft tissue sarcomas. [18] [19] [20] [21] [22] Based on our previous work showing that short hairpin (sh)RNA knockdown of LIN28A led to decreased KRAS expression 4 and the established links between the LIN28 pathway and mTOR, we hypothesized that mTOR is an important driver of AT/RT tumorigenicity.
Materials and Methods

Cell Culture
AT/RT cell lines BT12, BT16, BT37, and CHLA-06-ATRT have previously been described. 4, [23] [24] [25] BT12, obtained through the Children's Oncology Group cell repository, and BT16 were supplied by Dr Peter J. Houghton and Dr Jackie Biegel. 25 BT37 was derived from a human xenograft originating at St Jude Children's Research Hospital. 24 CHLA-06-ATRT was generated from pediatric AT/RT human tumor obtained from Children's Hospital of Los Angeles. 23, 24 Cell lines were authenticated by short tandem repeat DNA identity testing by the Johns Hopkins Genetic Resources Core Facility. Cell lines were confirmed to lack expression of INI1 by western blotting. TAK228, cisplatin, and everolimus were obtained from Selleck Chemicals and dissolved in dimethyl sulfoxide (DMSO) for in vitro experiments.
Growth Assays
Bromodeoxyuridine incorporation assays were performed by incubating cells with 100 µM 5-bromo-2ʹ-deoxyuridine (BrdU; Sigma-Aldrich) for 6 hours as described previously. 4 Anti-BrdU antibody was used per the manufacturer's direction (Sigma B-2531) at 1:500 dilution. To assess relative growth, cells were plated in 96-well plates in triplicate at densities of 2000 cells per well. Proliferation was measured at 0, 2, 4, and 6 days using the colorimetric CellTiter 96 MTS assay (Promega).
Death Assays
Immunofluorescence assays were performed as previously described, 4 using cleaved caspase-3 primary antibody at a dilution of 1:400 (Cell Signaling Technology #9661).
Western Blotting
Western blots were performed as previously described. 26 Specific antibodies were used as per the manufacturer's instructions: pAKT (Ser473; 4060), AKT (4691), pS6(S235/236; 2211), S6 (2317), cleaved poly(ADP-ribose) polymerase (c-PARP) (9541), LIN28A (3978), phosphorylated 4E-binding protein 1 (p4EBP1) (Thr37/46; 2855), 4EBP1 (9644), MAPK (9102), pMAPK (T202/Y204; 4370) (all from Cell Signaling Technologies), and ACTIN (47778) (Santa Cruz Biotechnology). Densitometry was performed using ImageJ v1.440 software as previously described. 27 
Synergy Experiments
Synergy experiments were completed per guidelines described by Chou and Talay 28 using a constant ratio of agents. Values were captured with the colorimetric CellTiter 96 MTS assay (Promega). Data and analysis were
Importance of the study
Atypical teratoid/rhabdoid tumors are the most common brain tumors of infancy. An intensive cisplatinbased regimen is the standard of care for AT/RT, but high rates of drug resistance lead to a median survival of 6 to 11 months. There is tremendous need for novel therapies that will complement and improve current therapies. We are the first to identify the mTOR pathway as an important driver of AT/RT tumorigenicity and describe a significant therapeutic benefit of mTOR inhibition with the dual TORC1/2 inhibitor TAK228 in orthotopic xenograft models of AT/RT. We also identify synergistic activity between TAK228 and cisplatin in AT/RT that could reduce drug resistance by enhancing cisplatin-induced cytotoxicity. This study provides the preclinical justification for the use of TAK228 in the treatment of AT/RT.
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processed via CompuSyn program for drug combinations and for general dose-effect analysis (http://www.combosyn.com).
Viral Infections and Short Hairpin Constructs
Lentivirus vectors encoding shRNA constructs against LIN28A were purchased from Sigma (TRCN0000021800, TRCN0000021802, and TRCN00000803). To produce the required lentiviral particles, 293T cells were transfected with vesicular stomatitis virus G (VSVG) envelope plasmid, delta 8.9 gag/pol plasmid, and the plasmid of interest using Fugene transfection reagent (Roche) per the manufacturer's instructions as described previously. 4 Supernatants were collected at 48, 72, and 96 hours and stored at 4°C. For infection of AT/RT cell lines, adherent cells and neurospheres were dissociated into single cells with gentle titration and Accutase, respectively, and incubated with the lentivirus containing LIN28A-shRNA, or pLKO empty vector. After 48 hours in culture, infected cells were selected using 1-2 µg/mL puromycin. All experiments were performed within 14 days of lentiviral infection.
Retroviral Induction of AKT
Constitutively active pBABE-Puro-Myr-Flag-AKT1 was a gift from William Hahn (Addgene plasmid #15294 29 ). pBABE puro empty vector was used as a negative control. Retroviruses were produced using 293GP cells transfected with 0.3 µg of VSVG envelope plasmid and 6 µg retroviral plasmid of interest, using Fugene 6 (Promega). Viral supernatants were pooled 48, 72, and 96 hours posttransfection and filtered (0.45 µm). Virus was added to exponentially growing cultures of BT37 cells. After 48 hours, transduced cells were selected using puromycin (1-2 µg/mL, SigmaAldrich) for 5 days. Induced expression of AKT in puromycin-selected cells was confirmed using immunoblotting.
SiRNA Transfection
Control small interfering (si)RNA was purchased from GE Dharmacon. SiRNA of rapamycin-insensitive companion of mTOR (RICTOR) (ON-TARGET plus SMARTpool, Dharmacon) was resuspended to 20 μM stock in 1× siRNA buffer and stored in single use aliquots at −20°C. Transfection was per manufacturer's instructions as previously described. 30 
Intracranial Xenograft Tumors
For animal care and anesthesia, "Principles of Laboratory Animal Care" (NIH publication No. 86-223, revised 1985) was followed, using a protocol approved by the Johns Hopkins Animal Care and Use Committee, in compliance with United States Animal Welfare Act regulations and Public Health Service Policy. Intracranial xenografts were produced in anesthetized animals as previously described. 26 Intracranial injection guide holes were produced by twirling an 18-gauge beveled needle and 2.5 × 10 5 viable cells (BT12) or 1 × 10 4 viable cells (CHLA-06-ATRT) injected in 5 µL of growth medium into the right striatum through a needle connected to a Hamilton syringe. Cells were injected using the following coordinates: anteroposterior = 3 mm; mediolateral = 2 mm; dorsoventral = 3 mm. The day after injection, mice were treated with 1 mg/ kg TAK228 orally 5 days a week versus oral administration of vehicle control (0.5% methylcellulose solution with 5% sucrose). This dose, when adjusted for body surface area, falls within the range of TAK228 doses used in clinical trials. [31] [32] [33] The combination study included 4 groups of 10 animals each: vehicle control; cisplatin 2 mg/kg intraperitoneal (i.p.) injections once weekly; TAK228 1 mg/ kg orally 5 days a week; combination of cisplatin 2 mg/ kg i.p. weekly; and TAK228 1 mg/kg orally 5 days a week. Animals were sacrificed upon signs of distress suggestive of an intracranial mass lesion such as neurologic deficits, poor grooming, and cachexia. For studies of development of resistance to TAK228, animals showing clinical signs of significant tumor burden were treated with TAK228 four hours prior to sacrifice. Immediately after sacrifice, areas of clear tumor infiltration were excised and snap frozen in liquid nitrogen and subsequently processed for western blotting.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism or Excel (Microsoft) software. All tests were 2 sided unless indicated otherwise, P-values <0.05 were considered significant.
Primary Brain Tumor Samples
Brain tumor specimens were procured by the department of pathology at St Jude Children's Research Hospital with institutional review board approval. All samples were de-identified.
Immunohistochemistry
Immunohistochemistry was performed on tissue microarrays (TMAs) containing cores from 18 AT/RTs. Formalin fixed paraffin-embedded tissue was utilized to construct TMAs. For each tumor, 2 cores measuring 0.6 mm diameter were used per array. Antigen unmasking was performed with hot sodium citrate pH 6.0 × 30 minutes followed by 3% hydrogen peroxide × 30 minutes and 0.4% Tris-buffered saline × 30 minutes. Slides were blocked with 4% normal goat serum × 1 hour and were incubated overnight at 4°C with primary antibodies. The following primary antibodies were used: 1:50 pS6 (S235/236; Cell Signaling Technologies #2211) and 1:70 pAKT (Ser473; Cell Signaling Technologies #4060). AT/RT tissue cores were scored by a neuropathologist (C.G.E.) using H-scores (H) (0-200), which were obtained by multiplying the intensity of stain (0: no stain, 1: weak stain, 2: strong stain) by percentage (0-100) of neoplastic cells showing the staining intensity. Tumors were scored for pAKT and pS6 as being 
Results
Knockdown of LIN28A Protein Expression Reduces mTOR Expression in AT/RT
To determine the impact of LIN28A on mTOR activity, we used lentiviral shRNA constructs to suppress LIN28A expression and measured the subsequent change in mTOR activation. Effective knockdown was confirmed by western blot with >70% reduction of LIN28A protein expression in CHLA-06-ATRT and BT37 compared with pLKO transduced cell lines (Fig. 1A) . Western blot was performed for pS6 and pAKT (Ser473) as readouts for activation of mTORC1 and mTORC2, respectively. shRNA knockdown of LIN28A in CHLA-06-ATRT led to >50% decrease in pAKT (Ser473) and >25% reduction in pS6 compared with pLKO control (Fig. 1A) , and in BT37 >70% decrease in pAKT (Ser473) and >25% reduction in pS6 (Fig. 1A) .
AT/RT Primary Human Tumors Have Elevated Levels of mTOR Activity with mTORC2 More Broadly and Intensely Activated Compared with mTORC1
We have previously shown that LIN28A is upregulated in AT/RTs. 4 To determine if AT/RTs have similar high level 
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activation of mTOR, we performed immunohistochemistry (IHC) for pS6 and pAKT (Ser473) using a TMA containing 18 primary AT/RTs. H-score was determined by a neuropathologist (C.G.E.) evaluating the percentage of cells stained and intensity of staining in each tumor sample. Mammalian TORC2 was activated more broadly and intensely than mTORC1. Phospho-AKT (Ser473) was detected in all 18 AT/ RT tumor samples (Fig. 1B) , and 87% had an H-score >50. Phospho-S6 was detected in 65% of tumors (Fig. 1C) but activation was lower compared with pAKT (Ser473), with 22% of tumors having an H-score >50.
Targeting the mTOR Pathway Slows AT/RT Tumor Growth
We pharmacologically inhibited the mTOR pathway with the dual TORC1/2 inhibitor TAK228. Phospho-S6, p4EBP1, and pAKT (Ser473) were strongly suppressed at 10 nM dosing of TAK228 and more fully at 100 nM (Fig. 2B,  Supplementary Figure S1 ) in all cell lines. Phosphorylated mitogen-activated protein kinase was unaffected by TAK228 (Supplementary Figure S1) , underscoring the specificity of TAK228 for TORC1/2. Treatment with 10 nM TAK228 decreased growth at day 6 compared with DMSO control in CHLA-06-ATRT by 59.4% (P < 0.001), BT12 by 50.8%, (P < 0.001), BT37 by 28.2% (P = 0.021), and BT16 by 58.9% (P < 0.001); all P-values by t-test. TAK228 at 100 nM dosing prevented growth in all 4 cell lines ( Fig. 2A,  Supplementary Fig. S2A ).
Targeting the mTOR Pathway in AT/RT Slows Cell Proliferation and Induces Apoptosis
To investigate the mechanism of TAK228's suppression of cell growth, we performed assays of proliferation and apoptosis. TAK228 treatment significantly reduced proliferation as measured by BrdU incorporation at 48 hours in all cell lines (Supplementary Figure S3) . Treatment with 100 nM TAK228 decreased BrdU incorporation compared with DMSO controls in CHLA-06-ATRT by 29.8% (P < 0.001), BT12 by 16.8% (P = 0.0398), and BT37 by 31.9% (P < 0.001). TAK228 treatment induced apoptosis after 48 hours at 100 nM concentrations as measured by cleaved caspase-3 (CC3) immunofluorescence assay compared with DMSO control (Fig. 2C) . TAK228 caused an increase in apoptosis of 44.2% in CHLA-06-ATRT (P = 0.008), 17.6% in BT12 (P = 0.006), and 44.8% in BT37 (P = 0.005; all P-values by t-test).
TAK228 Inhibits Both mTORC1 and mTORC2 Activation and Slows AT/RT Cell Growth More Effectively than Everolimus
To determine whether dual inhibition of mTORC1 and mTORC2 is necessary to decrease the tumorigenicity of AT/RT, we compared TAK228 treatment in parallel with the mTORC1 inhibitor, everolimus. TAK228 effectively inhibited activation of both mTORC1 and mTORC2, while everolimus inhibited mTORC1 activation but had no effect on mTORC2 (Supplementary Figure S4A) . TAK228 slowed cell growth more effectively in each of the 4 cell lines compared with everolimus (BT12, 81.7% reduction in growth with TAK228 treatment compared with DMSO control vs 53.9% reduction in growth with everolimus compared with DMSO control; P < 0.001; BT37 55.5% vs 39.1%; P = 0.004; CHLA-06-ATRT, 75.0% vs 17.2% P = 0.004; BT16, 68.2% vs 29.2% P < 0.001, by t-test; Supplementary Figure S4B ). In contrast to the induction of apoptosis with TAK228 treatment, everolimus had little impact on apoptosis (Supplementary Figure S4C) . These experiments were conducted using the minimal effective dose to inhibit mTOR activation (10 nM TAK228 and 1 nM everolimus).
TAK228 Crosses the Blood-Brain Barrier to Inhibit the mTOR Pathway and Significantly Extends Survival in Orthotopic AT/RT Tumor Models
TAK228 treatment extended survival in mice bearing BT12 orthotopic xenografts from a median of 23 days in the vehicle control to 39 days in the TAK228 treated mice (P = 0.002; log-rank test; Fig. 3A) . In mice bearing highly aggressive CHLA-06-ATRT orthotopic xenografts, median survival increased from 14 days in vehicle controls to 24 days in TAK228 treated animals (P = 0.02, log-rank test; Fig.  3B ). Western blot of tumor tissue taken at time of sacrifice showed that oral administration of TAK228 crossed the blood-brain barrier in sufficient concentration to inhibit the phosphorylation of S6 (>85% reduction) and AKT (Ser473; >50% reduction; Fig. 3A, B ).
TAK228 Combines with Cisplatin to Synergistically Inhibit AT/RT Cell Growth
Since cisplatin is a mainstay of chemotherapy for AT/ RT and AKT is an established mechanism by which cells escape cisplatin-induced cell death, 1, 34 we hypothesized that dual TORC1/2 inhibition with TAK228 would potentiate cisplatin therapy in AT/RT. Combined TAK228 and cisplatin treatment inhibited cell growth more than the additive effect of each medication administered alone (Fig. 4A,  Supplementary Figure S2B ). We also combined TAK228 and cisplatin therapy at 5 equal dose ratios ranging from 25% of the half-maximal inhibitory concentration (IC 50 ) to 4× IC 50 and measured the effect on cell growth via MTS assays. This combination worked synergistically to slow cell growth as determined by CompuSyn using the method of Chou and Talay, 26 with CIs <1.0 at most dose levels (values less than 1 indicate synergy; Supplementary Fig. S5 ).
The Combination of TAK228 and Cisplatin Treatment Increases Apoptosis
To confirm and extend the results of the synergy testing, we treated CHLA-06-ATRT and BT37 cell lines with cisplatin and TAK228 at the IC 25 for each drug. The combination of TAK228 with cisplatin induced significantly higher rates of apoptosis compared with monotherapy with TAK228 or cisplatin (35.3% of cells in combination group as determined by CC3 immunofluorescence assay vs 5.4% TAK228 and 20.4% cisplatin; P = 0.004 by ANOVA; Fig. 4B ). This experiment was repeated and confirmed by c-PARP expression (combination therapy in BT37 led to 13.2× increase in c-PARP expression, CHLA-06-ATRT 7.5× increase in c-PARP expression; Fig. 4C ). In contrast, cisplatin and everolimus at the IC 25 for each drug did not synergize to increase c-PARP expression (Supplementary Figure S4C ).
TAK228 Combined with Cisplatin Improves Overall Survival of Mice Bearing AT/RT Orthotopic Xenografts
The combination of TAK228 with cisplatin therapy significantly extended survival in mice bearing BT12 orthotopic xenografts compared with each medication alone and vehicle control (vehicle control P < 0.001, cisplatin P < 0.001, TAK228 P = 0.016 by log-rank test; Fig. 4D ). Median survival of vehicle control and cisplatin alone groups were both 20 days. TAK228 alone extended survival to a median of 29 days. The combination of TAK228 with cisplatin therapy extended median survival to 40 days. Zero mice in control, cisplatin, or TAK228 treated cohorts were alive at 62 days. Remarkably, 40% of mice in the combined TAK228/cisplatin treated arm were alive at this time point.
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Knockdown of mTORC2 Activity Sensitizes AT/ RT Cells to Cisplatin-Induced Apoptosis
To isolate the impact of mTORC2 inhibition and confirm the on-target effect of TAK228 in its synergistic activity with cisplatin, we knocked down mTORC2 activity in BT16 with siRNA targeted at RICTOR and treated cells with cisplatin therapy. We chose BT16 because this cell line expresses relatively high levels of pAKT (Ser473) and is resistant to cisplatin. 35 We confirmed knockdown of mTORC2 activity with western blot for pAKT (Ser473) (Fig. 5A) . Cisplatin therapy led to a greater induction of apoptosis in RICTOR knockdown cells as determined by increased c-PARP expression (Fig. 5A ).
Forced Expression of AKT in AT/RT Cells Suppresses Cisplatin-Induced Apoptosis
To further elucidate the impact of the mTOR pathway on cellular response to cisplatin, we forced the activation of mTOR by infecting BT37 cells with retrovirus encoding constitutively active, myristoylated AKT. 27 We chose BT37 because this cell line expressed lower levels of pAKT (Ser473) at baseline compared with other AT/RT lines. We verified increased pAKT (Ser473) expression by western blot (Fig. 5B ). BT37 cells with forced AKT expression were protected from cisplatin-induced apoptosis compared with empty vector control cells as determined by c-PARP expression (Fig. 5C ) and CC3 assay (Fig. 5D ).
Discussion
Atypical teratoid/rhabdoid tumors are aggressive tumors with very poor survival. 1 We have previously identified in AT/RT high-level LIN28 expression, which is a somatic cell reprogramming and stem cell factor. 4 We demonstrate here that downregulation of LIN28A is associated with suppression of mTOR activation in AT/RT. Since LIN28 has well-established roles regulating AKT and PI3K through the let-7 tumor suppressing miRNAs in other systems, it is likely that the high levels of LIN28 in AT/RT contribute to elevated expression of the mTOR effector pathways pS6 and pAKT (Ser473). Our results are concordant with a previous case report showing high-level activation of mTOR in 
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one patient with AT/RT. 36 The mTOR pathway thus serves as a rational therapeutic target in AT/RT.
AT/RT primary tumors have recently been subdivided into 3 groups based on expression profiling-tyrosinase (TYR), sonic hedgehog (SHH), and myelocytomatosis (MYC). 37 Our TMA has been stained for MITF (microphthalmia-associated transcription factor; defining the TYR subgroup), and both TYR and non-TYR AT/RT tumors express robust levels of pS6 and pAKT (Ser473) (data not shown). BT12 and CHLA-06-ATRT express significant MYC protein, suggesting that they may represent tumors from this subgroup while BT16 and BT37 do not express MYC (data not shown). However, all 4 cell lines are sensitive to TAK228. These results indicate that targeting mTORC1/2 may be an efficacious therapy regardless of AT/RT subgroup.
Mammalian TORC1 inhibitors such as rapamycin and everolimus have been tested in cancer for years but have little effect on the mTORC2 complex. [38] [39] [40] We show that the mTORC2 pathway is more broadly and strongly upregulated in AT/RT compared with mTORC1. Parallel experiments with everolimus show that dual mTORC1/2 inhibition with TAK228 more effectively reduces AT/RT growth and induces apoptosis. These data suggest that dual mTORC1/2 inhibition is necessary for effective mTOR targeting in AT/RT. Our results are concordant with a previous drug screen showing that mTORC1/2 inhibitors had activity in vitro in AT/RT. 41 Although TAK228 nearly doubled median survival of 2 AT/RT orthotopic xenograft models, animals eventually succumbed to their tumors. Treatment of mice showing clinical signs of significant tumor burden with TAK228 four hours prior to sacrifice showed that the compound was still penetrating the brain and inhibiting pS6 and pAKT (Ser473) (Fig. 3) . TAK228 resistance was therefore not likely due to upregulation of p-glycoprotein or other efflux pumps and may be due to a more fundamental mechanism that may confer sensitivity to targeting by other pharmacologic agents. The pharmacokinetics of TAK228 in human subjects suggest that oral dosing leads to a C max at 1-2 hours and clearance of TAK228 from plasma in approximately 8 hours. 33 The periodic inhibition of mTOR that TAK228 likely provides in vivo argues for pairing TAK228 with another drug, such as cisplatin, to maximize the proapoptotic properties of mTORC1/2 kinase inhibition and thereby enhance tumor cell killing.
The combination of cisplatin and TAK228 induced high rates of apoptosis and significantly extended survival in AT/ RT orthotopic xenografts. Elevated expression of mTORC2 has been identified in many highly drug resistant, deadly tumors. 30, [42] [43] [44] [45] [46] We found that forced AKT expression in low mTORC2-expressing AT/RT protects cells from cisplatininduced apoptosis while RICTOR knockdown to decrease mTORC2 activity sensitizes cells to cisplatin-induced apoptosis. These data suggest that mTORC2 expression contributes to AT/RT drug resistance by protecting tumor cells from the cytotoxic effects of cisplatin. These results are concordant with other studies showing AKT inhibition of apoptosis via phosphorylation of BCL2-associated death promoter (BAD) and caspase-9. 34 Targeted inhibition of mTORC2 with TAK228 could be added to conventional AT/RT therapy to sensitize tumors to cisplatin therapy, potentially reducing drug resistance and improving overall survival.
TAK228 is currently in phase I/II clinical studies in adult patients using a variety of administration schedules, ranging from daily to once weekly dosing (NCT02601209). 33 TAK228 is available through the Cancer Therapeutics Evaluation Program, and an early phase study of TAK228 in adult glioblastoma is currently under way (NCT02133183). No phase I pediatric studies of TAK228 have yet been undertaken. The addition of TAK228 to standard chemotherapies should be further explored, as it may decrease rates of resistance in AT/RT and improve overall survival.
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